How does the USPTO define “printed publication” for prior art purposes?

The USPTO’s definition of “printed publication” for prior art purposes is broad and evolving. According to MPEP 2128: “The term “printed publication” refers to such publications as books, magazines, journals, microfilm, computer databases, and Internet publications.” This definition is not limited to traditional printed materials but includes various forms of media that can disseminate information.…

Read More

How does the USPTO define “persons skilled in the art” for enablement purposes?

The USPTO’s definition of “persons skilled in the art” is crucial for understanding enablement requirements. According to MPEP 2164.05(b): “The specification need not disclose what is well-known to those skilled in the art and preferably omits that which is well-known to those skilled and already available to the public.” Key points about the USPTO’s definition…

Read More

How does the USPTO define ‘necessarily present’ in the context of inherency?

How does the USPTO define ‘necessarily present’ in the context of inherency? The concept of ‘necessarily present’ is crucial in understanding inherency in patent law. According to the MPEP 2112, a feature or characteristic is considered ‘necessarily present’ if it is an inevitable consequence of the prior art teachings, even if it was not explicitly…

Read More

How does the USPTO define “mathematical concepts” as abstract ideas?

The USPTO, in MPEP 2106.04(a), defines mathematical concepts as a category of abstract ideas. According to the MPEP: “Mathematical concepts” refers to mathematical relationships, mathematical formulas or equations, and mathematical calculations.“ The MPEP further elaborates on these subcategories: Mathematical relationships: Relationships between variables or numbers, such as a ratio or organizing information through mathematical correlations…

Read More

How does the USPTO define direct self-replication of biological materials?

The United States Patent and Trademark Office (USPTO) defines direct self-replication of biological materials in MPEP 2403.01 as follows: “Direct self-replication includes those situations where the biological material reproduces by itself.” This means that the biological material can reproduce independently, without requiring the presence of another self-replicating biological material. The MPEP indicates that representative examples…

Read More

How does the USPTO define ‘composition of matter’ for patent eligibility?

How does the USPTO define ‘composition of matter’ for patent eligibility? The USPTO defines ‘composition of matter’ as one of the four categories of patent-eligible subject matter under 35 U.S.C. § 101. According to the MPEP 2106.03: “Compositions of matter” are chemical compounds, mechanical mixtures, gases, and other materials. This category encompasses: Chemical compounds (e.g.,…

Read More

How does the USPTO define “abstract ideas” in patent eligibility determinations?

The USPTO’s definition of “abstract ideas” in patent eligibility determinations is outlined in MPEP 2106.04(a). Abstract ideas are considered judicial exceptions to patent eligibility. The MPEP states: “The abstract idea exception includes the following groupings of subject matter, when recited as such in a claim limitation(s) (that is, when recited on their own or per…

Read More

How does the USPTO decide whether to merge multiple reexamination proceedings?

The decision to merge multiple reexamination proceedings is made by the Central Reexamination Unit (CRU) Director or their delegate, typically after reexamination is ordered for the second request. The decision is based on several factors: The need for “special dispatch” in conducting reexamination proceedings, as mandated by 35 U.S.C. 305. The stage of the first…

Read More

How does the USPTO determine if a biological material is “known and readily available”?

How does the USPTO determine if a biological material is “known and readily available”? The USPTO considers several factors to determine if a biological material is “known and readily available,” which may negate the need for a deposit. According to MPEP 2404: “The Office will accept commercial availability as evidence that a biological material is…

Read More

How does the USPTO determine if a depository is acceptable?

The United States Patent and Trademark Office (USPTO) has specific criteria for determining if a depository is acceptable for biological materials. According to MPEP 2405: “The Commissioner may determine that a depository is acceptable if the depository:” Maintains biological material viability for 30 years or 5 years after the most recent request, whichever is longer…

Read More